Systematic review: Hypomagnesaemia induced by proton pump inhibition

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 5, 2012, Pages 405-413

  Hess, M W ^a   Hoenderop, J G J ^a   Bindels, R J M ^a   Drenth, J P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MAGNESIUM; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

DRUG INDUCED DISEASE; DRUG RECHALLENGE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; GENDER; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAGNESIUM EXCRETION; MAGNESIUM URINE LEVEL; PRIORITY JOURNAL; PROTON PUMP INHIBITOR INDUCED HYPOMAGNESEMIA; REVIEW; RISK FACTOR; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT DURATION;

CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL DISEASES; HUMANS; MAGNESIUM; MAGNESIUM DEFICIENCY; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84864668473     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05201.x     Document Type: Review

References (61)

1. Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR,. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007; 102: 2648-54.
2. Abu-Sneineh A, Tam W, Schoeman M, et al,. The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett's oesophagus. Aliment Pharmacol Ther 2010; 32: 1023-30.
3. Guimaraes EV, Guerra PV, Penna FJ,. Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole. Ther Clin Risk Manag 2010; 6: 531-7.
4. McKeage K, Blick SK, Croxtall JD, Lyseng-Williamson KA, Keating GM,. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2008; 68: 1571-607.
5. Olbe L, Carlsson E, Lindberg P,. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003; 2: 132-9.
6. Shi S, Klotz U,. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64: 935-51.
7. Kirchheiner J, Glatt S, Fuhr U, et al,. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65: 19-31.
8. Shin JM, Besancon M, Simon A, Sachs G,. The site of action of pantoprazole in the gastric H+/K(+)-ATPase. Biochim Biophys Acta 1993; 1148: 223-33.
9. Forgacs I, Loganayagam A,. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2-3.
10. Johnstone J, Nerenberg K, Loeb M,. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165-77.
11. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB,. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-60.
12. Leonard J, Marshall JK, Moayyedi P., Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol, 2007. 102: 2047-56.
13. Bajaj JS, Zadvornova Y, Heuman DM, et al,. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104: 1130-4.
14. Yang YX, Lewis JD, Epstein S, Metz DC,. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53.
15. Roux C, Briot K, Gossec L, et al,. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009; 84: 13-9.
16. Gau JT, Yang YX, Chen R, Kao TC,. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012; 21: 553-9.
17. Melville C, Shah A, Matthew D, Milla P,. Electrolyte disturbance with omeprazole therapy. Eur J Pediatr 1994; 153: 49-51.
18. Subbiah V, Tayek JA,. Tetany secondary to the use of a proton-pump inhibitor. Ann Intern Med 2002; 137: 219.
19. Nealis TB, Howden CW,. Is there a dark side to long-term proton pump inhibitor therapy? Am J Ther 2008; 15: 536-42.
20. Lodato F, Azzaroli F, Turco L, et al,. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010; 24: 193-201.
21. Cederberg C, Rohss K, Lundborg P, Olbe L,. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993; 28: 179-84.
22. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ,. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778-81.
23. Insogna KL,. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009; 104: S2-4.
24. Maeda Y, Kojima N, Araki Y, Uno T, Nishigaki K, Inaba N,. Does a proton pump inhibitor cause hypokalemia? Intern Med 2011; 50: 1045-50.
25. Epstein M, McGrath S, Law F,. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355: 1834-6.
26. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW,. Omeprazole and refractory hypomagnesaemia. BMJ 2008; 337: a425.
27. Cundy T, Dissanayake A,. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69: 338-41.
28. Francois M, Levy-Bohbot N, Caron J, Durlach V,. Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris) 2008; 69: 446-8.
29. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW,. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009; 151: 755-6.
30. Kuipers MT, Thang HD, Arntzenius AB,. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med 2009; 67: 169-72.
31. Doornebal J, Bijlsma R, Brouwer RM,. An unknown but potentially serious side effect of proton pump inhibitors: hypomagnesaemia. Ned Tijdschr Geneeskd 2009; 153: A711.
32. Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E,. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010; 56: 168-74.
33. Mackay JD, Bladon PT,. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010; 103: 387-95.
34. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R,. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010; 56: 112-6.
35. Cundy T, Mackay J,. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011; 27: 180-5.
36. Furlanetto TW, Faulhaber GA,. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 2011; 171: 1391-2.
37. Ayuk J, Gittoes NJ,. How should hypomagnesaemia be investigated and treated? Clin Endocrinol (Oxf) 2011; 75: 743-6.
38. Quasdorff M, Mertens J, Dinter J, Steffen HM,. Recurrent Hypomagnesemia With Proton-Pump Inhibitor Rechallenge. Ann Intern Med 2011; 155: 405-7.
39. Macias AG, Lahuerta JI, De Castro MA, Palacios EL,. Severe hypomagnesemia related to omeprazole. Rev Clin Esp 2011; 211: 488-9.
40. Fernandez-Fernandez FJ, Sesma P, Cainzos-Romero T, Ferreira L,. Hypomagnesemia related to the use of omeprazole with negative result for mutation in the TRPM6 gene. Med Clin (Barc) 2011; 137: 188-9.
41. Fernandez-Fernandez FJ, Sesma P, Cainzos-Romero T, Ferreira-Gonzalez L,. Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med 2010; 68: 329-30.
42. Callejas Diaz A, Montero Hernandez E, Gil Navarro M, Tutor-Ureta P, Yebra Bango M, Vargas Nunez JA,. Omeprazole and hypomagnesemia. Rev Clin Esp 2011; 211: e30-3.
43. Bhatt SP, Khandelwal P, Nanda S, Stoltzfus JC, Fioravanti GT,. Serum magnesium is an independent predictor of frequent readmissions due to acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2008; 102: 999-1003.
44. Sasaki T, Nakayama K, Yasuda H, et al,. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc 2009; 57: 1453-7.
45. Bjornsson E, Abrahamsson H, Simren M, et al,. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24: 945-54.
46. Topf JM, Murray PT,. Hypomagnesemia and hypermagnesemia. Rev Endocr Metab Disord 2003; 4: 195-206.
47. Reinhart RA,. Magnesium deficiency: recognition and treatment in the emergency medicine setting. Am J Emerg Med 1992; 10: 78-83.
48. Chou CL, Chen YH, Chau T, Lin SH,. Acquired bartter-like syndrome associated with gentamicin administration. Am J Med Sci 2005; 329: 144-9.
49. Ries F, Klastersky J,. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8: 368-79.
50. Ledeganck KJ, Boulet GA, Horvath CA, et al,. Expression of renal distal tubule transporters TRPM6 and NCC in a rat model of cyclosporine nephrotoxicity and effect of EGF treatment. Am J Physiol Renal Physiol 2011; 301: F486-93.
51. Dimke H, van der Wijst J, Alexander TR, et al,. Effects of the EGFR inhibitor erlotinib on magnesium handling. J Am Soc Nephrol 2010; 21: 1309-16.
52. Quamme GA,. Effect of furosemide on calcium and magnesium transport in the rat nephron. Am J Physiol 1981; 241: F340-7.
53. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ,. Enhanced passive Ca2 + reabsorption and reduced Mg2 + channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005; 115: 1651-8.
54. Ahmadi F, Naseri R, Lessan-Pezeshki M,. Relation of magnesium level to cyclosporine and metabolic complications in renal transplant recipients. Saudi J Kidney Dis Transpl 2009; 20: 766-9.
55. Hoenderop JG, Bindels RJ,. Calciotropic and magnesiotropic TRP channels. Physiology (Bethesda) 2008; 23: 32-40.
56. Lajer H, Daugaard G,. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47-58.
57. Ray S, Delaney M, Muller AF,. Proton pump inhibitors and acute interstitial nephritis. BMJ 2010; 341: c4412.
58. Meyer TE, Verwoert GC, Hwang SJ, et al,. Genome-wide association studies of serum magnesium, potassium and sodium concentrations identify six loci influencing serum magnesium levels. PLoS Genet 2010; 6.
59. Thongon N, Krishnamra N,. Omeprazole decreases magnesium transport across Caco-2 monolayers. World J Gastroenterol 2011; 17: 1574-83.
60. Konrad M, Schlingmann KP, Gudermann T,. Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol 2004; 286: F599-605.
61. Fleming CR, George L, Stoner GL, Tarrosa VB, Moyer TP,. The importance of urinary magnesium values in patients with gut failure. Mayo Clin Proc 1996; 71: 21-4.